IN2014DN09240A - - Google Patents

Info

Publication number
IN2014DN09240A
IN2014DN09240A IN9240DEN2014A IN2014DN09240A IN 2014DN09240 A IN2014DN09240 A IN 2014DN09240A IN 9240DEN2014 A IN9240DEN2014 A IN 9240DEN2014A IN 2014DN09240 A IN2014DN09240 A IN 2014DN09240A
Authority
IN
India
Prior art keywords
combination
treatment
11beta
medicament
human
Prior art date
Application number
Inventor
Germo Hans Gericke
Herbert Anton Schmid
Lutomirsky Mario Roberto Maldonado
Li Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN09240A publication Critical patent/IN2014DN09240A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a combination which comprises (a) a somatostatin analogue and (b) a 11beta hydroxylase inhibitor; each in free form or in the form of a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of diseases associated with increased stress hormone levels; a commercial package or product comprising such a combination; and to a method of treatment of a warm blooded animal, especially a human.
IN9240DEN2014 2012-04-12 2013-04-10 IN2014DN09240A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN09240A true IN2014DN09240A (en) 2015-07-10

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9240DEN2014 IN2014DN09240A (en) 2012-04-12 2013-04-10

Country Status (13)

Country Link
US (1) US9333234B2 (en)
EP (1) EP2836228B1 (en)
JP (1) JP6383352B2 (en)
KR (1) KR102136214B1 (en)
CN (1) CN104321074B (en)
AU (1) AU2013246908B2 (en)
BR (1) BR112014025058B1 (en)
CA (1) CA2869442C (en)
ES (1) ES2980806T3 (en)
IN (1) IN2014DN09240A (en)
MX (1) MX362533B (en)
RU (1) RU2663455C2 (en)
WO (1) WO2013153129A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33904B1 (en) * 2010-01-14 2013-01-02 Novartis Ag Use of adrenal hormone change factor
TWI707682B (en) * 2014-07-07 2020-10-21 瑞士商瑞科戴迪股份有限公司 Pharmaceutical dosage forms
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
KR102197526B1 (en) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 Differential diagnosis of ectopic Cushing syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334742A (en) * 1998-07-30 2002-02-06 研究及应用科学协会股份有限公司 Application method of somatostatin analogue lanreotide
RU2259375C2 (en) * 2001-04-09 2005-08-27 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Somatostatin agonists
GT200600381A (en) * 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
CN102666535B (en) * 2009-11-30 2015-02-25 诺华股份有限公司 Imidazole derivatives as aldosterone synthase inhibitors
MA33904B1 (en) * 2010-01-14 2013-01-02 Novartis Ag Use of adrenal hormone change factor
WO2013131879A1 (en) * 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide

Also Published As

Publication number Publication date
AU2013246908A1 (en) 2014-10-23
CA2869442A1 (en) 2013-10-17
CN104321074B (en) 2017-09-08
BR112014025058B1 (en) 2022-07-12
AU2013246908B2 (en) 2016-06-30
CN104321074A (en) 2015-01-28
MX362533B (en) 2019-01-23
JP2015512923A (en) 2015-04-30
EP2836228B1 (en) 2024-03-20
MX2014012321A (en) 2015-09-24
ES2980806T3 (en) 2024-10-03
BR112014025058A2 (en) 2017-06-20
US20150087588A1 (en) 2015-03-26
EP2836228A1 (en) 2015-02-18
RU2014145351A (en) 2016-06-10
KR20150004831A (en) 2015-01-13
WO2013153129A1 (en) 2013-10-17
CA2869442C (en) 2020-09-08
JP6383352B2 (en) 2018-08-29
US9333234B2 (en) 2016-05-10
KR102136214B1 (en) 2020-07-22
RU2663455C2 (en) 2018-08-06

Similar Documents

Publication Publication Date Title
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
TN2015000278A1 (en) Autotaxin inhibitors
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MY188382A (en) Spirocyclic inhibitors of cathepsin c
MX2017002816A (en) Pyrazolopyridine derivatives and their use in therapy.
EA025518B9 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
IN2015DN00528A (en)
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2016000294A (en) Pharmaceutical composition for a sustained release of lanreotide.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
IN2014DN09240A (en)
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017014776A (en) Pharmaceutical combination of everolimus with dactolisib.
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2020005310A (en) Combination product comprising dicycloplatin and preparation method and use thereof.
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
MA39009A (en) Compositions pharmaceutiques comprenant un agent actif
WO2015126151A3 (en) Composition for wound healing comprising massa medicata fermentata extract
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
MY159675A (en) Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
TH149179A (en) Pharmaceutical compositions, pharmaceutical forms, processes for preparing such compositions and forms, methods of treatment and use of such compositions and forms.